NCT02784756|CompletedDMC
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
QFT-CMV
Loading search results
QFT-CMV
Sponsor study identifier
interventional
134
2 countries
6
Study Start
June 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2020
Actual (reported)Study Completion
April 2020
Actual (reported)The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ transplant patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2020
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 10, 2016
Actual (reported)May 27, 2016
Actual (reported)June 2016
Date type not reportedThis date has not been verified as actual or estimated.
February 2020
Actual (reported)April 2020
Actual (reported)Symptomatic CMV disease
Number of participants with symptomatic CMV disease (including viral syndrome and tissue invasive disease) at 1 year post-transplant.
1 year
Occurrence of CMV viremia
1 year
positive vs. negative cell-mediated immunity assays
1 year
All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Alberta Hospital
Edmonton, Alberta, T6G 2G3, Canada
St. Paul's Hospital - Providence Health
Vancouver, British Columbia, V6Z 1Y6, Canada
London Health Sciences Centre
London, Ontario, N6A 4V2, Canada
St. Michael's Hospital
Toronto, Ontario, M5C 2T2, Canada
University Health Network, Toronto General Hospital
Toronto, Ontario, M5G 2N2, Canada
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Gibson L. An Interferon-gamma Release Assay for Evaluation of Cell-mediated Immunity in Infants With Congenital Cytomegalovirus Infection. Clin Infect Dis. 2021 Aug 2;73(3):374-375. doi: 10.1093/cid/ciaa700. No abstract available.
Atul Humar, MD
University Health Network, Toronto
Deepali Kumar, MD
University Health Network, Toronto
134 participants (actual enrollment reported by the registry).
First Submitted
February 10, 2016
First Posted
May 27, 2016
Study Start
June 2016
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
February 2020
Actual (reported)Study Completion
April 2020
Actual (reported)Last Updated
August 2, 2022
Record last verified: 2022-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: